NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Price, News & Analysis $30.89 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.83 -0.06 (-0.19%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Viking Therapeutics Stock (NASDAQ:VKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viking Therapeutics alerts:Sign Up Key Stats Today's Range$30.29▼$30.9250-Day Range$28.40▼$36.0152-Week Range$22.96▼$43.15Volume1.22 million shsAverage Volume2.30 million shsMarket Capitalization$3.59 billionP/E RatioN/ADividend YieldN/APrice Target$95.50Consensus RatingModerate Buy Company Overview Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders. The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions. Viking conducts Phase 2 clinical trials for these candidates, evaluating safety, tolerability and efficacy across multiple patient populations. Viking Therapeutics maintains operations across the United States, engaging with clinical research sites to enroll patients in its ongoing studies. The company also collaborates with academic institutions and regulatory agencies to advance trial designs and biomarker strategies that support its drug development objectives. Under the leadership of President and Chief Executive Officer David A. Woodhouse, Viking has built a management team with extensive experience in endocrinology, metabolic disease and biopharmaceutical development. The company’s strategic focus remains on progressing its pipeline through clinical milestones and exploring opportunities to extend its proprietary technology platform into additional indications.AI Generated. May Contain Errors. Read More Viking Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreVKTX MarketRank™: Viking Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 148th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViking Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 3 strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialViking Therapeutics has a consensus price target of $95.50, representing about 209.2% upside from its current price of $30.89.Amount of Analyst CoverageViking Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viking Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viking Therapeutics are expected to grow in the coming year, from ($4.67) to ($4.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viking Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.60% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 8.92.Change versus previous monthShort interest in Viking Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.49 News SentimentViking Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Viking Therapeutics this week, compared to 7 articles on an average week.Search Interest70 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.MarketBeat Follows38 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 850% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $149,912.00 in company stock, which represents 0.0042% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $149,912.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders5.30% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Viking Therapeutics' insider trading history. Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VKTX Stock News HeadlinesA Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent ReturnsMay 25 at 12:10 PM | finance.yahoo.comIs Viking Therapeutics a Top Takeover Target?May 23 at 4:31 PM | fool.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 25 at 1:00 AM | Behind the Markets (Ad)2 Stocks That Could Realistically Double by 2030May 22 at 9:46 AM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 22 at 2:28 AM | americanbankingnews.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | finance.yahoo.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | prnewswire.comViking Therapeutics Faces Timeline Risk—But Upside Could Be HugeViking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside...May 1, 2026 | marketbeat.comSee More Headlines VKTX Stock Analysis - Frequently Asked Questions How have VKTX shares performed this year? Viking Therapeutics' stock was trading at $35.18 at the beginning of the year. Since then, VKTX shares have decreased by 12.2% and is now trading at $30.89. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $0.36. Read the conference call transcript. When did Viking Therapeutics IPO? Viking Therapeutics (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. Who are Viking Therapeutics' major shareholders? Viking Therapeutics' top institutional investors include Pictet Asset Management Holding SA (0.60%), Dimensional Fund Advisors LP (0.47%), Principal Financial Group Inc. (0.45%) and Bank of New York Mellon Corp (0.39%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Matthew W Foehr, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton, Neil William Aubuchon and Sarah Kathryn Rouan. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Invesco QQQ (QQQ), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings4/29/2026Today5/25/202646th Annual William Blair Growth Stock Conference6/02/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 VKTX's financial health is in the Green zone, according to TradeSmith. VKTX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VKTX CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Viking Therapeutics$95.50 High Price Target$125.00 Low Price Target$38.00 Potential Upside/Downside+209.2%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$359.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.31% Return on Assets-65.35% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book7.15Miscellaneous Outstanding Shares116,110,000Free Float109,952,000Market Cap$3.59 billion OptionableOptionable Beta0.72 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VKTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
